NewGenIvf Group (NASDAQ:NIVF – Get Free Report) is projected to post its resultson Thursday, July 30th. Analysts expect the company to announce earnings of $556.20 per share and revenue of $2.8720 million for the quarter.
NewGenIvf Group (NASDAQ:NIVF – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($861.72) earnings per share (EPS) for the quarter. The business had revenue of $1.42 million during the quarter. On average, analysts expect NewGenIvf Group to post $14 EPS for the current fiscal year and $28 EPS for the next fiscal year.
NewGenIvf Group Stock Down 4.5%
Shares of NewGenIvf Group stock opened at $1.05 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. The business has a 50-day moving average of $1.88 and a two-hundred day moving average of $6.78. NewGenIvf Group has a 1 year low of $1.01 and a 1 year high of $568.53.
Analyst Ratings Changes
Check Out Our Latest Analysis on NewGenIvf Group
Insider Activity
In other news, major shareholder Financial Lp Hrt sold 28,439 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $2.40, for a total value of $68,253.60. Following the sale, the insider directly owned 18,187 shares in the company, valued at $43,648.80. The trade was a 60.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 31.80% of the stock is owned by corporate insiders.
NewGenIvf Group Company Profile
NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.
NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.
Read More
- Five stocks we like better than NewGenIvf Group
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
- Wintrust: A Quiet Regional Bank Posting Loud Results
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.
